MAPT and Alzheimer disease: In recent years, the consistent failure of pharmacological approaches targeting traditional AD targets such as Aβ and tau protein together with the existing number of drugs to be tested in pre-dementia stages of the disease has left no effective disease-modifying treatment of AD in sight.